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Abstract
Introduction: C-C chemokine receptor type 7 (CCR7) plays an important role in chemotactic and metastatic
responses in various cancers, including breast cancer. In the present study, the authors demonstrated that
microRNA (miRNA) let-7a downregulates CCR7 expression and directly influences the migration and invasion of
breast cancer cells.
Methods: The expression of CCR7, its ligand CCL21, and let-7a was detected in breast cancer cell lines and in
breast cancer patient tissues. Synthetic let-7a and an inhibitor of let-7a were transfected into MDA-MB-231 and
MCF-7 breast cancer cells, respectively, and cell proliferation, cell migration, and invasion assays were performed. To
confirm the fact that 3’UTR of CCR7 is a direct target of let-7a, a luciferase assay for the reporter gene expressing
the let-7a binding sites of CCR7 3’UTR was used. An in vivo invasion animal model system using transparent
zebrafish embryos was also established to determine the let-7a effect on breast cancer cell invasion.
Results: First, a higher expression of both CCR7 and CCL21 in malignant tissues than in their normal counterparts
from breast cancer patients was observed. In addition, a reverse correlation in the expression of CCR7 and let-7a in
breast cancer cell lines and breast cancer patient tissues was detected. Synthetic let-7a decreased breast cancer cell
proliferation, migration, and invasion, as well as CCR7 protein expression in MDA-MB-231 cells. The let-7a inhibitor
reversed the let-7a effects on the MCF-7 cells. The 3’UTR of CCR7 was confirmed as a direct target of let-7a by
using the luciferase assay for the reporter gene expressing let-7a CCR7 3’UTR binding sites. Notably, when
analyzing in vivo invasion, MDA-MB 231 cells after synthetic let-7a transfection were unable to invade the vessels in
zebrafish embryos.
Conclusions: The results from the present study suggest that targeting of CCL21-CCR7 signaling is a valid approach for
breast cancer therapy and that let-7a directly binds to the 3’UTR of CCR7 and blocks its protein expression, thereby
suppressing migration and invasion of human breast cancer cells. Furthermore, the present study underscores the
therapeutic potential of let-7a as an antitumor and antimetastatic manager in breast cancer patients.
Introduction
Breast cancer is the most common cancer in women
and is ranked second only to lung cancer in deaths
caused by cancer [1]. Although many advanced treat-
ments have resulted from improving clinical instruments
and methods, metastasis still leads to cancer mortality
and poor prognosis [2]. Therefore, inhibition of metasta-
sis can be a major goal, and we noted that C-C chemo-
kine receptor type 7 (CCR7) is a reasonable therapeutic
target in breast cancer therapy, because expression of
CCR7 is reportedly correlated with lymphatic metastasis
and poor prognosis in breast cancers [3-5]. CCR7 is a
member of the G protein-coupled receptor (GPCR)
family and is commonly expressed on memory T cells,
B cells, and mature dendritic cells [4,6]. CCR7 can be
activated by the binding of cytokines CCL19 and CCL21
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[5]. Usually, naïve T cells enter lymphoid tissues from
the blood via its ligands, CCL19 and CCL21, which are
expressed by mature dendritic cells [7]. Consequently,
these ligands are important for the adaptive immune
responses between dendritic cells, B cells, T cells, and
the inflammatory response. Therefore, a possible role of
CCR7 in cancer development and metastasis is its asso-
ciation with cancers, as well as being linked to the
expression of its ligands, CCL19 and CCL21 [8].
Recently, CCL21 was shown to be secreted not only by
lymphatic endothelial cells (LECs), but also by the can-
cer cells themselves [9]. Supposedly, a ligand of CCR7 is
secreted by the cancer cells themselves and allows the
cancer cells to migrate to the lymphoid tissues; thus,
blocking CCR7 in cancer cells could inhibit metastasis
without the immune cell responses.
Therefore, we studied the inhibition of CCR7 expres-
sion in breast cancer cells. Recently, numerous articles
demonstrated that microRNA (miRNA) suppresses the
expression of several cancer-related genes and reduces
tumorigenesis and metastasis in breast and several other
cancers. Specifically, the relative roles of CCR7 and
miRNA in breast cancer metastasis were examined, and
thus, the CCR7 3’UTR binding miRNA was searched by
using the TargetScan prediction program. The results
showed that only the let-7 family binds CCR7 3’UTR.
Let-7 was the first identified miRNA originally isolated
from Caenorhabditis elegans. The let-7 family has multi-
ple functions. Within the let-7 family, let-7a expression
increases after differentiation and in mature tissue, but is
barely detectable in the embryonic stage [10]. Let-7a was
found to act as a tumor suppressor directly regulating
RAS and HMGA2 oncogenes by interacting with the
3’UTR [11-13]. Reduced levels of let-7a correlate with
elevated RAS expression in lung squamous carcinoma
[11]. Let-7a is involved in cell proliferation [14] and influ-
ences cancer metastasis in various tumors, including
breast cancer [15-17]. However, the mechanism of let-7a
action on metastasis-related genes is poorly understood.
In the present study, among the metastasis-related
genes as potential targets of let-7a, a reverse correlation
between CCR7 and let-7a expression was observed in
breast cancer patient tissues and breast cancer cell lines,
and let-7a specifically influenced CCR7 downexpression.
Let-7a was also found to target CCR7 3’UTR directly,
thereby downregulating breast cancer cell migration and
invasion. Last, by using zebrafish embryo models, confir-
mation of the let-7a effects observed in vitro was
obtained in vivo. Through the previously mentioned stu-
dies, we focused on the interrelation of the two agents,
let-7a and CCR7, in search of promising molecular tar-
gets to inhibit metastasis and for potential antimetastatic
agents for possible use in breast cancer therapy.
Materials and methods
Tissues
Tissue samples were obtained at biopsy from 15 breast
cancer patients (five infiltrating ductal cancer, one meta-
plastic cancer matrix-producing type, seven invasive
ductal cancer, one infiltrating cribriform cancer, and
one atypical medullary cancer) and their normal coun-
terparts at Samsung Medical Center in Korea. The pro-
tocol for the study was approved by the institutional
review board (IRB) at Samsung Medical Center (1). All
participants provided written informed consent and the
use of tissues for comprehensive experiments of breast
cancer informed consent. Immediately after biopsy, the
tissue samples were frozen in liquid nitrogen and stored
at -70°C until use.
Cell culture and transfection
Human breast cancer cell lines, SK-BR-3, MDA-MB-
231, MCF-7, Hs-578T, T47D, ZR-75-1, and JIMT-1
were obtained from the ATCC and maintained in RPMI
1640 and Dulbecco modified Eagle medium (DMEM)
containing 10% fetal bovine serum (FBS) and 1% anti-
biotics (Invitrogen, San Diego, CA, USA). The dsRNA
used in transfection experiments as a scrambled siRNA
(scRNA) was 5’-UCACAACCUCCUAGAAAGAGUA
GA-3’, synthetic let-7a: 5’-UGAGGUAGUAGGUU-
GUAUAGUU-3’, CCL21 siRNA: 5’- GUACAGCC
AAAGGAAGAUUUU-3’, and CCR7 siRNA: 5’- GCTG
GTCGTGTTGA CCTAT-3’. All of these were synthe-
sized by Genolution Company in Korea. In addition,
commercial anti-let-7a oligonucleotide was purchased
from Panagene in Korea. The dsRNA was transfected
into MDA-MB-231 and MCF-7 cell lines by using Lipo-
fectamine RNAiMAX and Lipofectamine 2000 reagents
(Invitrogen), according to the reagent manufacturer’s
instructions. The MDA-MB-231 and MCF-7 cell lines
were harvested 2 days after transfection, and various
analyses were performed.
RNA isolation and reverse transcription polymerase chain
reaction
Total RNA was isolated from seven breast cancer cell lines
and 10 breast cancer patients’ tissues, respectively,
by using TRIzol reagent (Invitrogen) and following
the manufacturer’s instructions. Reverse transcription
polymerase chain reaction (RT-PCR) was performed
by using the Reverse Transcription System (Promega,
Madison, WI, USA). PCR experiments were performed
after reverse transcription. The primers for b-actin
were 5’-AGCCTCGCCTTTGCCGA-3’ and 5’-CTGGTG
CCTGGGGCG-3’; for CCR7, 5’-GATGCGATGCTC
TCTCATCA-3’ and 5’-TGTAGGGCAGCTGGAAGACT-
3’, and for CCL21, 5’-GCCTTGCCACACTCTTTCTC-3’
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and 5’-CAAGGAAGAGGTGGGGTGTA-3’. The PCR was
performed by using Ex-Taq (TaKaRa) methods.
microRNA real-time RT-PCR
A TaqMan One-step RT-PCR Master Mix Reagents kit,
purchased from Applied Biosystems (ABI, Foster City,
CA, USA) was used. Amplification and detection were
performed by using a 7900HT Sequence Detection Sys-
tem (ABI) with 40 cycles of denaturation at 95°C (15
seconds) and annealing/extension at 60°C (60 seconds).
This was preceded by reverse transcription at 50°C for
30 minutes and denaturation at 95°C for 10 minutes. To
quantitate mature miRNA, TaqMan MicroRNA Assays
kits were purchased from ABI to detect let-7a and a
control miRNA (RNU6B) (ABI). The protocol is two
steps, requiring reverse transcription with an miRNA-
specific primer, followed by real-time PCR with TaqMan
probes (ABI).
Western blot analysis
Protein was extracted from seven breast cancer cell lines
and 10 breast cancer patient tissue samples by using
RIPA buffer (Biosesang), including a protease inhibitor
cocktail (Sigma) and TRIzol reagent (Invitrogen),
according to the manufacturers’ instructions. Next,
Western blotting was performed by using anti-b-actin,
anti-CKR7 (CCR7), anti-IGF-1R (Santa Cruz) anti-c-
Myc, and anti-CDK4 (Cell Signaling) antibodies. The
signals were detected with an ECL kit (Amersham) by
following the manufacturer’s instructions.
Trans-filter migration and invasion assays
Trans-filter migration and invasion assays were per-
formed on MDA-MB-231 and MCF-7 cell lines in
serum-free DMEM with 8.0-μm pore inserts on a 24-
well Transwell (Corning Costar, Lowell, MA, USA). The
cell lines were transfected with synthetic let-7a, CCR7
siRNA, anti-let-7a, and scRNA for 1 day and then trans-
ferred to the upper chamber of the Transwell coated
with 0.5 mg/ml collagen type I (BD Bioscience) and a
1:15 dilution of Matrigel (BD Bioscience). Migrating and
invading cells were quantified after H&E staining.
Migration and invasion assays were performed after
transfection, as previously described [18].
The luciferase reporter plasmid constructions
The luciferase reporter constructs were generated by
introducing the CCR7 3’UTR carrying a let-7a binding
site into the pGL3 control vector (Promega). First, the
CCR7 3’UTR wild-type (WT) sequence was amplified
with PCR by using primers WT-FW (including Xba I
restriction enzyme sites) 5’-CTAGTCTAGAGC-
GACTCTTCTGCCTGG-3’ and WT-BW 5’- CTAGT
CTAGAGCCATTTACCAAAGACTTTTTTTTTC-3’
with MDA-MB-231 cDNA as a template, followed by
PCR for the CCR7 3’UTR mutant type (MUT) sequence
by using primers MUT-FW (including Xba I restriction
enzyme sites) 5’-CTAGTCTAGAAACAGAGGCTAT
TGTCCCC-3’ and MUT-BW 5’- CTAGTCTAGAGC-
CATTTACCAAAGACTTTTTTTTTC -3’ with MDA-
MB-231 cDNA as a template. PCR was performed with
pfu polymerase (SUN gene, Korea) methods. The result-
ing PCR fragments were cloned into the pGL3 vector by
using Xba I restriction enzyme sites, creating the pGL3
CCR7 3’UTR WT and pGL3 CCR7 3’UTR MUT con-
structs. All PCR products were verified by DNA
sequencing.
Luciferase assay
Luciferase assays were performed in HEK-293 cells.
HEK-293 cells were transfected with each of the plas-
mids (empty vector (EV), CCR7 3’UTR WT and CCR7
3’UTR MUT, as a let-7a binding site) together with syn-
thetic let-7a oligonucleotides and negative control RNA
in six-well plates. Forty-eight hours after transfection,
the cells were harvested and lysed. Luciferase assays
were performed on the lysates by using a luciferase
assay kit (Promega). The luciferase activity was normal-
ized to b-galactosidase.
Northern blot analysis
Total RNA was isolated from human breast cancer cell
lines by using TRIzol reagent (Invitrogen). RNA samples
(15 μg each) were loaded on 15% acrylamide denaturing
(urea) gels and then transferred onto nylon membranes.
The hybridization with [g-32P] ATP was performed at
37°C in a prehybridization solution (Clonetech) over-
night. The membrane was washed at 37°C twice with
1 × SSC [0.3 M trisodium citrate and 3.0 M sodium
chloride in high-purity dH2O, pH 7.0]. The oligonucleo-
tide probes used were 5’-AACTATACAA CCTAC-
TACCTCA-3’ with a sequence complementary to the
mature let-7a RNA. An oligonucleotide complementary
to the U6 RNA, 5’-GCAGGGGCCATGCTAATCTTC
TC TGTATCG-3’, was used to normalize expression
levels. Blots were stripped by boiling in 0.1% aqueous
SDS in DEPC water for 1 minute and reprobed several
times. As the loading control, tRNA stained with ethi-
dium bromide was used.
Cell-proliferation assay
Cell proliferation was measured with the MTT assay.
MDA-MB-231 and MCF-7 cells were plated in 96-well
culture plates (3 × 103 per well), followed by transfec-
tion of synthetic let-7a, CCR7 siRNA, anti-let-7a,
and scRNA. After 48 hours of incubation, the MTT
(0.5 mg/ml) (Sigma-Aldrich) was subsequently added to
each well (200 μl/well). After 4 hours of additional
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incubation, the MTT solution was discarded; and 200 μl
of DMSO (Amresco) was added, and the plate was sha-
ken gently. The absorbance was measured on an
enzyme-linked immunosorbent assay (ELISA) reader at
a wavelength of 570 nm.
Statistical analysis
Data are presented as mean ± SD from at least four to
five images obtained from three independent experi-
ments by using a microscope (×200), unless otherwise
indicated. Statistical analysis was performed with one-
way ANOVA by using Prism software and the Student t
test for comparison between groups. Data were consid-
ered significant if P < 0.05.
Results
CCR7 and its ligand CCL21 were highly expressed in
breast cancer cell lines and breast cancer patients
First, the expression of mRNA for CCR7 and its ligands
CCL19 and CCL21 was confirmed in breast cancer cell
lines (Figure 1a) and in malignant and normal tissues
from breast cancer patients (Figure 1b). CCR7 mRNA
was highly expressed in most breast cancer cell lines
and tissues from cancer patients. CCL19 expression was
weakly detected in the cell lines and patient tissues
(data not shown). However, CCL21 was more highly
expressed in MDA-MB-231 and MCF-7 cell lines than
in the other five breast cancer cell lines. A higher
expression of CCL21 in malignant tissues than in their
normal counterparts from breast cancer patients was
discovered. Therefore, the results suggest that CCR7 sig-
naling could be activated and affect cancer cells them-
selves by inducing strong expression of CCL21.
Reverse correlation between the expression of let-7a and
CCR7 in breast cancer cell lines
Downregulation of let-7a expression was reported in
breast cancer [19], and in the present study, the expres-
sion was determined with Northern blotting and quanti-
tative RT-PCR analysis (Figure 2a, b). Comparatively,
high and low let-7a expression was detected in MCF-7
and JIMT-1 cells and in MDA-MB-231 cells, respec-
tively. To determine whether any correlation existed
between the expression of let-7a and its target proteins
in breast cancer cell lines, the expression levels of the
predicted let-7a target proteins were examined, such as
CCR7, IGF-1R, c-Myc, and CDK4 (Figure 2c). Among
the target proteins, CCR7 showed a significant reverse
correlation with let-7a expression, suggesting that CCR7
could be regulated by let-7a in breast cancer cells.
Overexpression of let-7a decreases CCR7 expression as
well as cell proliferation, invasion, and migration in MDA-
MB-231 breast cancer cells
Synthetic let-7a was transfected into MDA-MB-231
cells, which express low levels of let-7a, and the change
in the expression level of predicted CCR7 target proteins
(Figure 3a) was evaluated. The expression of CCR7 and
CDK4 was downregulated by let-7a more than that of
IGF-1R and c-Myc. Recent studies have shown that both
let-7a and CCR7 influence cell proliferation, as well as
cancer cell invasion and migration [5,14,20]. To confirm
the results, MDA-MB-231 cells were transfected with
synthetic let-7a or CCR7 siRNA as a CCR7-silencing
positive control (Figure 3b). According to the results, a
small reduction in cell proliferation was detected by
silencing CCR7 with both synthetic let-7a and CCR7
siRNA in transfected MDA-MB-231 cells. Moreover,
both synthetic let-7a and CCR7 siRNA reduced cell
invasion and migration by less than half of the reduction
resulting from transfection with scRNA (Figure 3d, e).
The results suggest that CCR7 silencing has an inhibi-
tory effect on breast cancer cell proliferation, migration,
and invasion, and overexpression of let-7a has the same
effect as CCR7 silencing.
Downregulation of let-7a increases cell invasion,
migration, and proliferation in MCF-7 breast cancer cells
Next, the inhibitory effect of let-7a was determined by
using synthetic anti-let-7a oligo-nucleotides in MCF-7
breast cancer cells, which express a high level of let-7a
and a low level of CCR7, with a high level of CCL21
expression. After transfection with synthetic anti-let-7a,
the level of CCR7 expression increased (Figure 4a). The
Figure 1 Detection of mRNA expression levels of CCR7 and
CCL21. CCR7 and CCL21 mRNA expression levels were detected
with RT-PCR analysis in seven breast cancer cell lines (a) and five
breast cancer patient tissues (b). b-actin was used as a
normalization control.
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cell proliferation, migration, and invasion in MCF-7 cells
also were assayed. As expected, transfection with anti-
let-7a increased cell proliferation, invasion, and migra-
tion (Figure 4b-d). The results provided confirmation
that CCR7 expression and the consequent breast cancer
cell proliferation and motility are downregulated by
let-7a.
Let-7a regulation of cell migration and invasion is
dependent on CCR7 and its ligand CCL21
Additionally, the relation between let-7a and the
CCL21-CCR7 signaling pathway was confirmed. First,
CCL21-specific siRNA and synthetic let-7a were trans-
fected into MDA-MB-231 cell lines expressing high
levels of both CCL21 and CCR7 (Figure 5a and 5c).
After CCL21 siRNA and synthetic let-7a transfections,
downregulation of both CCL21 and CCR7 expression
was shown via RT-PCR and Western blot analysis (Fig-
ure 5a). In addition, the effect of cell migration and
invasion activity was confirmed through the cell migra-
tion and invasion assay, indicating that let-7a decreased
MDA-MB-231 cell migration and invasion activity,
dependent on CCR7 and CCL21 expression (Figure 5c).
Next, the anti-let-7a effect was also confirmed through
the transfection of CCL21 siRNA and synthetic anti-let-
7a in MCF-7 cell lines with a high expression of CCL21
and low expression of CCR7 (Figure 5b and 5d). After
siRNA of CCL21 and synthetic anti-let-7a transfections,
downregulation of CCL21 and overexpression of CCR7
expression was demonstrated by using RT-PCR and
Western blot analysis (Figure 5b). Additionally, the
effect of cell migration and invasion activity was con-
firmed by the cell migration and invasion assays, show-
ing anti-let-7a increased MCF-7 cell migration and
invasion activity, dependent on CCR7 and CCL21
expression (Figure 5d). These experiments showed that
let-7a regulates CCR7 and cell motility, dependent on
CCL21 expressions.
Let-7a directly regulates CCR7 expression by binding with
the 3’UTR of CCR7
To elucidate the role of let-7a in CCR7 protein expres-
sion, the CCR7 3’UTR was prepared in the pGL3 con-
trol luciferase vector, and luciferase activity was
evaluated after transfecting with synthetic let-7a (Figure
6). First, the let-7a binding site on CCR7 3’UTR was
predicted by using the TargetScan microRNA-binding
prediction program (Figure 6a). Next, the wild-type
(WT) constructs containing let-7a binding CCR7 3’UTR
and mutant type (MUT) constructs were prepared, in
which the binding site was deleted. After transfection
with scRNA or synthetic let-7a, the luciferase activity
Figure 2 Detection of basal expression levels of CCR7, IGF-1R, c-Myc, CDK-4, and let-7a in seven breast cancer cell lines. (a-b) Let-7a
expression levels in breast cancer cells, detected with Northern blot analysis (NB)(a) and real-time RT-PCR(b). U6 and RNU6B were used as a
normalization control. (c) Detection of protein expression levels of CCR7, IGF-1R, c-Myc, and CDK-4 by using Western blot analysis. b-actin was
used as a normalization control.
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Figure 3 Detection of changes in the expression of let-7a predicted target proteins and cell proliferation, cell migration, and invasion
of MDA-MB-231 breast cancer cells after transfection with synthetic let-7a. (a) After transfection with scRNA or synthetic let-7a, protein
expression of CCR7, IGF-1R, c-Myc, and CDK-4 was detected with Western blot analysis. (b) Proliferation of MDA-MB-231 cells was assessed with
MTT assay after transfection with scRNA, CCR7 siRNA, and synthetic let-7a, respectively. (c) Protein expression of CCR7 was detected with
Western blot analysis after transfection with scRNA, CCR7 siRNA, and synthetic let-7a, respectively. b-actin was used as a normalization control.
(d) Cell-migration assays and (e) invasion assays performed after transfection with scRNA, CCR7 siRNA, and synthetic let-7a, as described in
Materials and Methods, presented as a histogram (left panel) with cell photos (right panel) All the experiments were performed in triplicate
independently.
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was analyzed (Figure 6b). Synthetic let-7a transfection
had greater luciferase activity in the CCR7 3’UTR WT
construct than in the CCR7 3’UTR MUT construct. The
result suggests that let-7a directly regulates CCR7 pro-
tein expression through interaction with the 3’UTR of
CCR7.
Transfection of synthetic let-7a decreases in vivo breast
cancer cell invasion in zebrafish embryo animal models
To analyze the in vivo effect of let-7a on cancer cell
migration, zebrafish embryos having green fluorescent
protein (GFP)-labeled blood vessels were prepared as an
animal model. Red fluorescent protein (RFP)-labeled
MDA-MB-231 cells were transfected with synthetic let-
7a or CCR7 siRNA and injected into the abdomens of
the zebrafish embryos. After each time point, the cells
that migrated out into the blood vessels in the zebrafish
embryos were detected (Figure 7a), and the zebrafish
embryos containing the migrating cells were counted
(Figure 7b and Tables 2 and 3). Notably, control MDA-
MB-231 cells migrated into the trunk regions and
resided in the vessel of the trunk and/or tail of the zeb-
rafish embryos after injection of the cells into their
abdomens. However, synthetic let-7a or CCR7 siRNA-
transfected cells were not detected in the trunk or tail
vessels of the zebrafish embryos. The zebrafish embryos
in which the detected cells were migrating to the trunks
or tail vessels also were counted (Table 2). When using
Figure 4 Cell proliferation, cell migration, and invasion of MCF-7 breast cancer cell lines were increased after transfection with anti-
let7a. (a) Protein expression of CCR7 was detected with Western blot analysis after transfection with scRNA and anti-let-7a, respectively. b-actin
was used as a normalization control. After transfection with scRNA or anti-let7a, (b) cell proliferation by MTT analysis, (c) cell-migration assays,
and (d) invasion assays were performed, as described in Material and Methods, and the results of (c) and (d) presented as a histogram (left
panel) with cell photos (right panel). All experiments were performed in triplicate independently.
Kim et al. Breast Cancer Research 2012, 14:R14
http://breast-cancer-research.com/content/14/1/R14
Page 7 of 12
scRNA-transfected cells, breast cancer cell migration
was observed in nine of 21 zebrafish embryos, and no
cell migration was observed in embryos by using syn-
thetic let-7a or CCR7 siRNA-transfected cells. The
migrated cells in the trunks or tail vessels also were
counted (Table 3). Approximately 30% of control breast
cancer cells were able to migrate out from the embryo
abdomen, but none of the synthetic let-7a or CCR7
siRNA-transfected cells could do so. Collectively, the
data suggest that the zebrafish embryo model can be
used to monitor the migration of breast cancer cells in a
living animal, and let-7a overexpression or CCR7
silencing could cause a significant reduction in breast
cancer cell migration in vivo.
Reverse correlation between the expression of CCR7 and
let-7a in breast cancer patients
The expression of let-7a and CCR7 was examined in 15
breast cancer patients by quantitative RT-PCR analysis
and Western blotting, respectively (Figure 8). In seven of
15 breast cancer patients, let-7a expression was more
downregulated in malignant tissues than in normal coun-
terpart tissues (Figure 8a). In contrast, CCR7 expression
was higher in malignant tissues compared with normal
Figure 5 Let-7a regulates cell migration and invasion of MDA-MB-231 and MCF-7 cell lines, dependent on CCR-7-CCL21 signaling. (a)
mRNA expression of CCL21 and CCR7, and protein expression of CCR7 were detected with RT-PCR and Western blot analysis after transfection
with scRNA, synthetic let-7a, and CCL21 siRNA in MDA-MB-231 cells, respectively. b-actin was used as a normalization control. (b) mRNA
expression of CCL21 and CCR7, and protein expression of CCR7 were detected with RT-PCR and Western blot analysis after transfection with
scRNA, anti-let-7a, and CCL21 siRNA in MCF-7 cells, respectively. b-actin was used as a normalization control. (c) After transfection with scRNA,
synthetic let-7a, and CCL21 siRNA into MDA-MB-231cells, cell-migration assays and cell-invasion assays were performed (*, **P < 0.01 versus
control group). (d) After transfection with scRNA, synthetic anti-let-7a, and CCL21 siRNA into McF-7 cells, cell-migration assays and cell-invasion
assays were performed (*, **P < 0.01 versus control group). The assays were described in Material and Methods, and the results of (c) and (d) are
presented as a histogram. All experiments were performed in triplicate independently.
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counterpart tissues in 10 of 15 breast cancer patients
(Figure 8b). A reverse correlation of expression was also
found in tissues from six breast cancer patients.
Discussion
The miRNA is highly conserved noncoding RNA that
posttranscriptionally controls gene expression by
degradation of target mRNA and/or by the inhibition of
protein translation [15,21,22]. The miRNA contains an
average of 22 nucleotides and plays important roles in a
wide range of biologic processes, such as development,
cell growth, cell proliferation, and death [23]. The dereg-
ulation of miRNA, frequently detected in human can-
cers, has been established as contributing to cancer
Figure 6 Direct interaction between let-7a and 3’UTR of CCR7. (a) Preparation of the construct with the let-7a binding site on the 3’UTR of
CCR7, which was predicted by the TargetScan 4.1 database program. (b) Luciferase activity of CCR7 3’UTR luciferase reporters was detected after
synthetic let-7a transfection. Wild-type (WT) and mutant type (MUT) of CCR7 3’UTR luciferase reporters were prepared as described in the
Material and Methods section. Expression of b-galactosidase was used as a control for transfection normalization.
Figure 7 Detection of the migration of breast cancer cells in zebrafish embryos as an in vivo animal model. (a, b) RFP-labeled MDA-MB-
231 cells were transfected with synthetic let-7a, CCR7 siRNA, and scRNA, respectively, and injected into the center of the yolk sac of transgenic
zebrafish in which embryonic vessels are visualized with green fluorescence, as described in the Material and Methods section. After 1 day and 3
days of injections, RFP-labeled MDA-MB-231 cells were detected in GFP-labeled vessels by using a fluorescence microscope, and the results are
presented as a photograph in (a). The number of migrating cells was counted (b). The data were derived from three replicated experiments. The
scale bars are 200 μm and 50 μm in the last panels.
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progression and metastasis [24,25]. Additionally, miRNA
has been identified as potential oncogenes or tumor
suppressors [15,26].
Downregulation of let-7a was found in highly meta-
static human breast cancer patient tissues [19], and in
human breast cancer cells, such as MDA-MB-231 cells.
To clarify the role of let-7a in metastasis, potential let-
7a target genes were searched, specifically metastasis-
related genes, and their protein expression was exam-
ined after synthetic let-7a treatment. Notably, a reverse
correlation between levels of let-7a and CCR7 expres-
sion was found in both human breast cancer patient tis-
sues and in cancer cell lines. CCR7 is known to play an
important role in cancer metastasis [6]. We observed
decreasing MDA-MB-231 cell migration and invasion
when CCR7 expression was inhibited by synthetic let-7a.
In contrast, silencing (inhibition) of let-7a resulted in
increases in CCR7 expression, cell migration, and cell
invasion in MCF-7 breast cancer cells, consistent with
the results of CCR7 silencing by its specific siRNA.
Therefore, we suggest that let-7a reduces breast cancer
cell migration and invasion through the downregulation
of CCR7 expression.
Normally, CCR7 activity is regulated by CCL19 and
CCL21, which is secreted by cancer cells themselves and
allows cancer cells to migrate to the lymphoid tissues.
In the present study, CCL21 expression in breast cancer
cell lines and in breast cancer patients was evaluated. As
hypothesized, the expression levels of CCR7 and CCL21
were significantly increased in cancer cells and cancer-
ous tissues from patients. In addition, we confirmed that
CCR7 increased cell motility, dependent on CCL21
expression (Figure 5). The results suggest that CCL21
triggers the activation of CCR7 signaling through
CCL21 secreted from cancer cells in an autocrine
manner.
Based on our data, we can infer that let-7a regulates
the translation of CCR7, which is believed to be the
most common mechanism of miRNA targeting [27].
Let-7a targeting of CCR7 3’UTR was confirmed by
using a luciferase reporter gene carrying the 3’UTR of
CCR7 wild-type or a mutant type of the let-7a binding
site. The data showed the 3’UTR of CCR7 was a direct
target of let-7a. The effects of let-7a and CCR7 siRNA
silencing on breast cancer cell migration in vivo were
also confirmed by using a zebrafish embryo model. The
studies showed that synthetic let-7a- or CCR7 siRNA-
transfected cells exhibit reduced cell migration. The zeb-
rafish embryo model was established to study cell
migration in vivo because the RFP-labeled MDA-MB-
231 cells could be detected easily in transparent zebra-
fish embryos containing GFP-labeled vessels. Normal
MDA-MB-231 cells have the ability to migrate out into
the vessel and move toward the tail, whereas cells in
which CCR7 is silenced with synthetic let-7a or CCR7
siRNA lose this ability. Collectively, the results from the
present study demonstrate let-7a suppresses metastasis
through CCR7 target regulation and may be potentially
useful as an antimetastatic agent in breast cancer.
Conclusions
In the present study, we determined that let-7a sup-
pressed breast cancer cell migration and invasion by
downregulating CCR7 expression. Therefore, we suggest
that targeting of CCL21-CCR7 signaling is a convincing
Table 3 The number of migrated cells per tail vein of
zebrafish embryos that had migrating MDA-MB-231 (RFP)
cells transfected with let-7a, CCR7 siRNA and scRNA,
respectively
Transfection Cells in the tail vein/Total injected cells
0 day 1 day 3 day
Control 0/150 (0) 4/150 (3%) 42/150 (28%)
RFP scRNA 0/150 (0) 5/150 (3%) 45/150 (30%)
RFP let-7a 0/150 (0) 0/150 (0) 0/150 (0)
RFP CCR7 siRNA 0/150 (0) 0/150 (0) 0/150 (0)
Table 1 List of breast cancer patients
Number Sex/Age Pathologic diagnosis
1 F/54 Infiltrating ductal cancer
2 F/39 Metaplastic ca, matrix-producing type
3 F/60 Metaplastic ca, matrix-producing type
4 F/43 Invasive ductal cancer
5 F/63 Invasive ductal cancer
6 F/47 Invasive ductal cancer
7 F/46 Invasive ductal cancer
8 F/40 Invasive ductal cancer
9 F/54 Invasive ductal cancer
10 F/46 Invasive lobular cancer
11 F/52 Infiltrating ductal cancer
12 F/50 Infiltrating ductal cancer
13 F/51 Infiltrating ductal cancer
14 F/79 Infiltrating cribriform cancer
15 F/46 Atypical medullary cancer
Table 2 The number of zebrafish embryos with migrating
MDA-MB-231 (RFP) cells transfected with let-7a, CCR7
siRNA and scRNA, respectively
Transfection Embryos containing migrating cells/Total
embryos
0 (day) 1 (day) 3 (days)
Control 0/25 7/25 (28%) 9/23 (39%)
RFP scRNA 0/25 8/24 (33%) 9/21 (43%)
RFP let-7a 0/27 0/26 (0%) 0/24 (0%)
RFP CCR7 siRNA 0/24 0/24 (0%) 0/21 (0%)
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approach for improving breast cancer therapy and the
usefulness of let-7a as a direct regulator of this signal-
ing. In addition, the strong association between the loss
of let-7a expression and metastatic relapse suggests the
potential of let-7a in prognostic stratification of breast
cancer patients in addition to conventional clinical and
pathologic staging markers.
Abbreviations
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